Tropisetron Hydrochloride Oral Solution

Pharmacological action: This product is a potent and highly selective competitive antagonist of 5-hydroxytryptamine 3 (5-HT3) receptors in peripheral neurons and the central nervous system. Certain substances, including some chemotherapy drugs, can stimulate the chromaffin-like cells of the visceral mucosa to release 5-hydroxytryptamine, thereby inducing a vomiting reflex accompanied by nausea. This product mainly inhibits the vomiting reflex by selectively blocking the presynaptic 5-HT3 receptors of peripheral neurons. In addition, its antiemetic effect may also be related to its direct blocking of the central 5-HT3 receptors to inhibit the stimulation of the vagus nerve in the rear region.

The main ingredient of this product is tropisetron hydrochloride.

This product is in liquid form for oral administration.

Prevention and treatment of nausea and vomiting caused by cancer chemotherapy.

Adults: The maximum adult dose is 5 mg/day, once a day, and the course of treatment is 6 days. Intravenous administration on the first day: Dissolve 5 mg (1 ampoule) of tropisetron hydrochloride in 100 ml of commonly used infusion solution (such as normal saline, Ringer's solution or 5% glucose solution) and administer it by rapid intravenous drip or slow intravenous push before chemotherapy. On the 2nd to 6th day, it can be taken orally with water when getting up in the morning (at least 1 hour before breakfast). Children: It is generally not used in children. If it must be used due to medical conditions, refer to the following doses: The dose for children over 2 years old is 0.2 mg/kg, and the maximum can reach 5 mg/day. Intravenous administration on the first day: Dissolve tropisetron hydrochloride in 100 ml of commonly used infusion solution (such as normal saline, Ringer's solution or 5% glucose solution) and administer it by rapid intravenous drip or slow push before chemotherapy.

Tropisetron hydrochloride is usually well tolerated. Adverse reactions at the recommended dose are transient. Common adverse reactions include headache, dizziness, constipation, fatigue, and gastrointestinal dysfunction such as abdominal pain and diarrhea. A very small number of patients may experience transient blood pressure changes or allergic reactions. The former does not require special treatment, and the latter may improve after anti-allergic treatment.

It is contraindicated in patients who are allergic to tropisetron hydrochloride.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1. If tropisetron hydrochloride is used simultaneously with rifampicin or other liver enzyme inducing drugs (such as phenobarbital), the plasma concentration of tropisetron hydrochloride may be reduced. Therefore, patients with normal metabolism need to increase the dose (patients with poor metabolizers do not need to increase the dose). 2. Cytochrome P450 enzyme inhibitors such as cimetidine have little effect on the plasma concentration of tropisetron hydrochloride. Under normal use, there is no need to adjust the dose.

Sealed in a cool, dry place.

10ml:5mg (calculated according to C17H20N202)

24 months

Nanjing Haijing Pharmaceutical Co., Ltd.

• Founded in:

  1991-07-22

• Address:

  No. 23, Xinke 2nd Road, Jiangbei New District, Nanjing

• Tax NO.:

  9132019113491078X2

• Registered Funds:

  100.361879 yuan

• Website:

  Log in to view

• Email:

  Log in to view